vs
Avantor, Inc.（AVTR）与Liberty Energy Inc.（LBRT）财务数据对比。点击上方公司名可切换其他公司
Avantor, Inc.的季度营收约是Liberty Energy Inc.的1.6倍（$1.7B vs $1.0B），Avantor, Inc.净利率更高（3.1% vs 2.2%，领先0.9%），Liberty Energy Inc.同比增速更快（4.5% vs -1.4%），过去两年Avantor, Inc.的营收复合增速更高（-0.5% vs -6.2%）
Avantor是一家总部位于美国宾夕法尼亚州拉德诺的生物技术、化工及制药领域企业，前身为1904年成立的J.T. Baker，2010年正式更名，2019年在纽约证券交易所挂牌上市，股票代码为AVTR，为全球生命科学、医疗健康等行业客户提供核心产品与服务。
Liberty Energy Inc.是北美领先的能源服务供应商，专注为油气运营企业提供水力压裂及完井解决方案，服务覆盖美国主要页岩产区，供应低排放作业设备及定制化支持，帮助提升油气井生产效率。
AVTR vs LBRT — 直观对比
营收规模更大
AVTR
是对方的1.6倍
$1.0B
营收增速更快
LBRT
高出5.8%
-1.4%
净利率更高
AVTR
高出0.9%
2.2%
两年增速更快
AVTR
近两年复合增速
-6.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.7B | $1.0B |
| 净利润 | $52.4M | $22.6M |
| 毛利率 | 31.5% | — |
| 营业利润率 | 7.6% | 2.2% |
| 净利率 | 3.1% | 2.2% |
| 营收同比 | -1.4% | 4.5% |
| 净利润同比 | -89.5% | 64.8% |
| 每股收益（稀释后） | $0.08 | $0.14 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVTRLBRT
| Q1 26 | — | $1.0B | ||
| Q4 25 | $1.7B | $1.0B | ||
| Q3 25 | $1.6B | $947.4M | ||
| Q2 25 | $1.7B | $1.0B | ||
| Q1 25 | $1.6B | $977.5M | ||
| Q4 24 | $1.7B | $943.6M | ||
| Q3 24 | $1.7B | $1.1B | ||
| Q2 24 | $1.7B | $1.2B |
净利润AVTRLBRT
| Q1 26 | — | $22.6M | ||
| Q4 25 | $52.4M | $13.7M | ||
| Q3 25 | $-711.8M | $43.1M | ||
| Q2 25 | $64.7M | $71.0M | ||
| Q1 25 | $64.5M | $20.1M | ||
| Q4 24 | $500.4M | $51.9M | ||
| Q3 24 | $57.8M | $73.8M | ||
| Q2 24 | $92.9M | $108.4M |
毛利率AVTRLBRT
| Q1 26 | — | — | ||
| Q4 25 | 31.5% | 20.6% | ||
| Q3 25 | 32.4% | 18.7% | ||
| Q2 25 | 32.9% | 22.1% | ||
| Q1 25 | 33.8% | 22.1% | ||
| Q4 24 | 33.4% | 21.4% | ||
| Q3 24 | 32.9% | 26.2% | ||
| Q2 24 | 34.1% | 27.9% |
营业利润率AVTRLBRT
| Q1 26 | — | 2.2% | ||
| Q4 25 | 7.6% | 1.9% | ||
| Q3 25 | -40.0% | -0.3% | ||
| Q2 25 | 7.7% | 3.6% | ||
| Q1 25 | 9.3% | 1.9% | ||
| Q4 24 | 37.8% | 2.6% | ||
| Q3 24 | 7.3% | 9.4% | ||
| Q2 24 | 10.3% | 12.2% |
净利率AVTRLBRT
| Q1 26 | — | 2.2% | ||
| Q4 25 | 3.1% | 1.3% | ||
| Q3 25 | -43.8% | 4.5% | ||
| Q2 25 | 3.8% | 6.8% | ||
| Q1 25 | 4.1% | 2.1% | ||
| Q4 24 | 29.7% | 5.5% | ||
| Q3 24 | 3.4% | 6.5% | ||
| Q2 24 | 5.5% | 9.3% |
每股收益（稀释后）AVTRLBRT
| Q1 26 | — | $0.14 | ||
| Q4 25 | $0.08 | $0.08 | ||
| Q3 25 | $-1.04 | $0.26 | ||
| Q2 25 | $0.09 | $0.43 | ||
| Q1 25 | $0.09 | $0.12 | ||
| Q4 24 | $0.73 | $0.31 | ||
| Q3 24 | $0.08 | $0.44 | ||
| Q2 24 | $0.14 | $0.64 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $365.4M | $699.1M |
| 总债务越低越好 | $3.9B | $7.1M |
| 股东权益账面价值 | $5.6B | $1.9B |
| 总资产 | $11.8B | $4.4B |
| 负债/权益比越低杠杆越低 | 0.71× | 0.00× |
8季度趋势，按日历期对齐
现金及短期投资AVTRLBRT
| Q1 26 | — | $699.1M | ||
| Q4 25 | $365.4M | $27.6M | ||
| Q3 25 | $251.9M | $13.5M | ||
| Q2 25 | $449.4M | $19.6M | ||
| Q1 25 | $315.7M | $24.1M | ||
| Q4 24 | $261.9M | $20.0M | ||
| Q3 24 | $285.3M | $23.0M | ||
| Q2 24 | $272.6M | $30.0M |
总债务AVTRLBRT
| Q1 26 | — | $7.1M | ||
| Q4 25 | $3.9B | $246.6M | ||
| Q3 25 | $3.9B | — | ||
| Q2 25 | $4.2B | — | ||
| Q1 25 | $4.1B | — | ||
| Q4 24 | $4.1B | $190.5M | ||
| Q3 24 | $4.9B | — | ||
| Q2 24 | $5.1B | — |
股东权益AVTRLBRT
| Q1 26 | — | $1.9B | ||
| Q4 25 | $5.6B | $2.1B | ||
| Q3 25 | $5.6B | $2.1B | ||
| Q2 25 | $6.3B | $2.0B | ||
| Q1 25 | $6.1B | $2.0B | ||
| Q4 24 | $6.0B | $2.0B | ||
| Q3 24 | $5.6B | $2.0B | ||
| Q2 24 | $5.4B | $1.9B |
总资产AVTRLBRT
| Q1 26 | — | $4.4B | ||
| Q4 25 | $11.8B | $3.6B | ||
| Q3 25 | $11.7B | $3.5B | ||
| Q2 25 | $12.8B | $3.4B | ||
| Q1 25 | $12.3B | $3.4B | ||
| Q4 24 | $12.1B | $3.3B | ||
| Q3 24 | $12.8B | $3.3B | ||
| Q2 24 | $12.7B | $3.2B |
负债/权益比AVTRLBRT
| Q1 26 | — | 0.00× | ||
| Q4 25 | 0.71× | 0.12× | ||
| Q3 25 | 0.69× | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.67× | — | ||
| Q4 24 | 0.68× | 0.10× | ||
| Q3 24 | 0.89× | — | ||
| Q2 24 | 0.94× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $152.7M | — |
| 自由现金流经营现金流 - 资本支出 | $117.2M | — |
| 自由现金流率自由现金流/营收 | 7.0% | — |
| 资本支出强度资本支出/营收 | 2.1% | 13.1% |
| 现金转化率经营现金流/净利润 | 2.91× | — |
| 过去12个月自由现金流最近4个季度 | $495.0M | — |
8季度趋势，按日历期对齐
经营现金流AVTRLBRT
| Q1 26 | — | — | ||
| Q4 25 | $152.7M | $195.4M | ||
| Q3 25 | $207.4M | $51.5M | ||
| Q2 25 | $154.4M | $170.6M | ||
| Q1 25 | $109.3M | $192.1M | ||
| Q4 24 | $173.3M | $177.3M | ||
| Q3 24 | $244.8M | $244.5M | ||
| Q2 24 | $281.1M | $248.2M |
自由现金流AVTRLBRT
| Q1 26 | — | — | ||
| Q4 25 | $117.2M | $-10.0M | ||
| Q3 25 | $171.7M | $-67.2M | ||
| Q2 25 | $124.8M | $33.1M | ||
| Q1 25 | $81.3M | $58.2M | ||
| Q4 24 | $145.8M | $-26.2M | ||
| Q3 24 | $204.0M | $77.9M | ||
| Q2 24 | $235.3M | $112.2M |
自由现金流率AVTRLBRT
| Q1 26 | — | — | ||
| Q4 25 | 7.0% | -1.0% | ||
| Q3 25 | 10.6% | -7.1% | ||
| Q2 25 | 7.4% | 3.2% | ||
| Q1 25 | 5.1% | 6.0% | ||
| Q4 24 | 8.6% | -2.8% | ||
| Q3 24 | 11.9% | 6.8% | ||
| Q2 24 | 13.8% | 9.7% |
资本支出强度AVTRLBRT
| Q1 26 | — | 13.1% | ||
| Q4 25 | 2.1% | 19.8% | ||
| Q3 25 | 2.2% | 12.5% | ||
| Q2 25 | 1.8% | 13.2% | ||
| Q1 25 | 1.8% | 13.7% | ||
| Q4 24 | 1.6% | 21.6% | ||
| Q3 24 | 2.4% | 14.6% | ||
| Q2 24 | 2.7% | 11.7% |
现金转化率AVTRLBRT
| Q1 26 | — | — | ||
| Q4 25 | 2.91× | 14.28× | ||
| Q3 25 | — | 1.20× | ||
| Q2 25 | 2.39× | 2.40× | ||
| Q1 25 | 1.69× | 9.55× | ||
| Q4 24 | 0.35× | 3.42× | ||
| Q3 24 | 4.24× | 3.31× | ||
| Q2 24 | 3.03× | 2.29× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVTR
| Laboratory Solutions Segment | $1.1B | 67% |
| Bioscience Production Segment | $547.5M | 33% |
LBRT
暂无分部数据
